BACKGROUND & AIMS: Adalimumab is an efficacious therapy for active Crohn's disease,
but long-term data are scarce. We conducted an observational study to assess the long-term …

Infliximab, a chimeric monoclonal antibody, has profoundly modified the treatment of several
inflammatory diseases, but no satisfactory description of its pharmacokinetics is available. …

An enzyme-linked immunosorbent assay (ELISA) measuring serum infliximab concentrations
in treated patients was developed. Microtiter plates were sensitized with tumor necrosis …

The annual cost of eculizumab maintenance therapy in paroxysmal nocturnal hemoglobinuria
(PNH) and atypical hemolytic–uremic syndrome (aHUS) exceeds $300,000 per patient. A …

Objective The chimeric anti-tumor necrosis factor-α antibody infliximab is known to induce
antibodies-to-infliximab (ATI) in some treated patients. Immunogenicity in murine variable …

Partial ablation of the left fronto-parietal cerebral cortex decreases the number of spleen T
cells, impairs IgG-α SRBC and T mitogen-induced responses, and delays the response to …

Binkley and Davis1 recently identified a third variant of hereditary angioedema (HAE) in a
family of Italian origin. Clinical presentation was indistinguishable from HAE type I or II except …

Study objective To determine the value of the level of anti-topoisomerase I (anti-topo I) to
evaluate lung involvement defined by abnormal high-resolution computed tomography (HRCT) …

Cetuximab is an anti-epidermal growth factor receptor monoclonal antibody used in the
treatment of colorectal and head and neck cancers. Part of the interindividual differences in …

OBJECTIVE: To investigate a potential association between occupational risk factors and
severity markers of systemic sclerosis (SSc) defined by diffuse cutaneous extent, pulmonary …